Drug developer NanoViricides (NYSE-A:NNVC) Inc said it has successfully completed its phase Ia/Ib clinical trial of NV-CoV-2, its lead asset.
Involving healthy subjects, the study was concluded without any adverse events, a key element to early human studies.
NV-CoV-2's active ingredient, NV-387, has demonstrated early signs of effectiveness against various respiratory viruses, including all tested coronaviruses and respiratory syncytial virus (RSV).
This is attributed to NV-387's design, which mimics the host-side feature known as "sulfated proteoglycans" (S-PG). This biomimetic approach effectively disables the virus from infecting cells, drawing parallels with how antibiotics such as penicillins attack bacterial surfaces.
The broad-spectrum, cross-virus-families antiviral activity of NV-387 positions it as a potential game-changer in not only treating viral infections but also in rapidly responding to future pandemics, a need highlighted by the COVID-19 crisis.
NanoViricides (NYSE-A:NNVC)' innovative approach also addresses the challenge of viral variants. NV-387's mechanism of action, targeting host-side features that remain constant even as viruses mutate, makes it unlikely for viral variants to evade the drug. This is further reinforced by NV-387's wide spectrum of activity across multiple virus families.
In an update, investors were told the clinical trial, carried out at the Mahatma Gandhi Mission's Medical College & Hospital in Aurangabad, India, included various dosing cohorts.
NV-CoV-2 was administered orally using syrup and gummies, with the evaluation designed in two parts: a single-ascending-dose arm and a multiple-ascending-dose cohort.
Assessing the safety profile of NV-387, the trial revealed no adverse events during treatment or in the follow-up period.
This result is consistent with the compound's safety characteristics observed in pre-clinical studies. Notably, NV-387 has been found to be non-immunogenic, non-allergenic, non-mutagenic, and non-genotoxic in various pre-clinical animal model studies.
It is worth noting that certain existing antiviral drugs are often limited by significant dose-related toxicities.
According to research, the market for treatments to tackle RSV, which can seriously affect the very young and elderly, was worth just under $2 billion in 2022 and could total almost $9 billion by 2031.
Of course, there are far wider applications for a successful product of the ilk of NV-CoV-2 with broad-based applications.
Meanwhile, shares of NanoViricides (NYSE-A:NNVC) had added 6.5% on the news to trade around $1.14 on Monday afternoon.
--Updated with share price--